Ticrynafen and hydrochlorothiazide. A double-blind study of antihypertensive properties with an open crossover.
Twenty-eight patients completed a double-blind study of the antihypertensive effects of ticrynafen compared with those of hydrochlorothiazide. The results of blood pressure reduction were comparable in the two groups. After six months, 12 patients were crossed over to ticrynafen therapy from hydrochlorothiazide. They maintained their blood pressure reduction. The most striking difference between the two groups was in the uric acid response. The uric acid level in the patients receiving hydrochlorothiazide therapy rose from a baseline of 5.9 to 7.5 mg/dL (normal range, 3.0 to 8.0 mg/dL). The uric acid level of those patients receiving ticrynafen therapy decreased from a baseline of 6.4 mg/dL to a low of 3.3 mg/dL. In view of ticrynafen's appreciable antihypertensive and uric-acid-lowering effects, it appears to be a useful new antihypertensive drug.
D000328:Adult; D000368:Aged; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010642:Phenoxyacetates / Q000627:therapeutic use*; D010919:Placebos; D013876:Thiophenes / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D004232:Diuretics; D006016:Glycolates; D010642:Phenoxyacetates; D010919:Placebos; D013876:Thiophenes; D006852:Hydrochlorothiazide; D014527:Uric Acid